Medco "YOURxPLAN" Preferred List Includes 13 Schering Drugs, Cenestin
Executive Summary
The Merck-Medco/Reader's Digest "YOURxPLAN" prescription discount service includes 13 Schering-Plough drugs on its list of "select" products that generate cash refunds to enrollees.
You may also be interested in...
Who's Afraid Of Patent Losses? Merck, Schering, BMS Defenses Play Well
Merck has regenerating brands; Schering-Plough has desloratadine; Bristol-Myers Squibb has an 11th-hour patent and a combo replacement for a major single-ingredient expiration; and they all have recession-haven reputations.
Who's Afraid Of Patent Losses? Merck, Schering, BMS Defenses Play Well
Merck has regenerating brands; Schering-Plough has desloratadine; Bristol-Myers Squibb has an 11th-hour patent and a combo replacement for a major single-ingredient expiration; and they all have recession-haven reputations.
Merck/Schering Ezetimibe Deal Is Part Of Growing Ties Between Firms
Merck is edging away from its strict go-it-alone policy and sidling up a little closer to Schering-Plough in a series of deals - the most recent of which is a co-promotion agreement with Schering-Plough for the Phase III cholesterol absorption inhibitor ezetimibe.